iGMDRD586


Canonical SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OP(=O)(C)C)C)C)O)OC)C)C)C)OC

InChI: InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14-,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI Key: BUROJSBIWGDYCN-QHPXJTPRSA-N

Loading, please wait...
Standard Name
Pubchem CID
Drug Status
Drug Type
Standard NameRidaforolimus
Pubchem CID25200000
Drug StatusAlone
Drug TypeSmall Molecule

Drug-model tissue-cancer distribution: Bubble Plot

UTERUtissue: UTERU cancer: UTERUS model num: 0UTERUStissue: UTERUS cancer: Endometrial Carcinoma (UCEC) model num: 3

Drug-gene pathway enrichments

5reactome: Signal Transduction4reactome: Signaling by NTRKs4reactome: Immune System4reactome: Signaling by Receptor Tyrosine Kinases3kegg: Melanoma - Homo sapiens (human)3kegg: Endometrial cancer - Homo sapiens (human)3reactome: VEGFA-VEGFR2 Pathway3wikipathways: Focal Adhesion-PI3K-Akt-mTOR-signaling pathway3kegg: Prostate cancer - Homo sapiens (human)3wikipathways: Endometrial cancer

Drug-gene GO enrichments

4CC: cytoplasm4CC: cytosol3CC: plasma membrane3MF: 1-phosphatidylinositol-3-kinase activity3MF: protein binding2BP: angiogenesis2MF: phosphatidylinositol-4,5-bisphosphate 3-kinase activity2CC: mitochondrion2BP: negative regulation of phosphatidylinositol 3-kinase signaling2BP: negative regulation of protein kinase B signaling

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
3845 KRAS 1
5290 PIK3CA 1
5728 PTEN 1
Showing 1 to 3 of 3 rows

Gene in drug-gene network: Network Plot

Models in Ridaforolimus

Loading, please wait...
Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
No matching records found

​​​​